Status:
COMPLETED
Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line
Lead Sponsor:
Cairo University
Conditions:
Squamous Cell Carcinoma
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
Oral squamous cell carcinoma (OSCC) are considered as a one of the most malignant cancers. It has prognosis due to its distant metastasis and obvious destruction which lead to low survival rate. The ...
Detailed Description
Oral squamous cell carcinoma (OSCC) is considered the most common human body malignant tumor. It has poor prognosis regarding its distant lymph node metastasis and local destruction which lead to low ...
Eligibility Criteria
Inclusion
- All head and neck squamous cell carcinoma cell lines
- Licochalcone extracts
- Taxols group of chemotherapy
Exclusion
- Animal experimental studies
- Any cancer cell line other than squamous cell carcinoma cell lines.
- Any chemotherapeutics other than Taxols group.
Key Trial Info
Start Date :
February 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03292822
Start Date
February 15 2021
End Date
December 1 2023
Last Update
June 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt